Search PubMed⌕ Search

Biomedical subjects

G Michlmayr

Publications and source records attributed to G Michlmayr.

78 records · Page 5Linked to original sources
PubMedDate not supplied

Toxicity and preliminary results with a new eight-drug regimen (CEOP-IMVP-DEXA) in the treatment of aggressive lymphomas.

A combination of two non-cross-resistant regimens, CEOP and IMVP-Dexa given every 4 weeks, three to six times according to response was tested in patients with untreated histological proven high and intermediate grade non-Hodgkin's lymphoma. To date eight Austrian centres entered 37 patients in this multicentre trial. Data are available from 33 patients, three were excluded, two because of pretreatment, one because of wrong histology. Twenty-five patients are evaluable for response, 21 had a complete and three a partial remission, two of them entered a complete remission after radiotherapy to residual disease, resulting in a complete remission rate of 92 per cent. Only one patient progressed during therapy. Until now three patients relapsed after achieving a remission. Observation time is 0.4-23.8 months, median 8.8 months. Toxicity was primarily hematologic with 53.3 per cent of patients having granulocyte nadirs below 0.5 x 10(9)/L and 3.3 per cent below 0.1 x 10(9)/L. Although 60 per cent of patients had infections, there was only one life-threatening infection in an AIDS patient. CEOP-IMVP-Dexa can be safely given even in smaller hematologic centres and is able to achieve a high rate of complete responses in patients with high and intermediate grade malignant non-Hodgkin's lymphomas.

Adult↗
PubMedDate not supplied

[Preoperative autologous blood collection under erythropoietin stimulation. Preliminary results in patient selection, erythropoietin dosage and administration].

In a randomised study we have evaluated the influence of erythropoietin (EPO) on the yield of autologous blood in elective surgery (total hip replacement). The study was performed placebo controlled in 82 patients: 25 patients received 200 IE EPO/kg 2 x/week i.v. over 3 weeks (group C), 30 patients 100 IE EPO in the same schedule (group B), and 27 patients received placebo (group A). All patients were treated with 3 x 250 mg Fe-sulfate p.o. during the study time. The number of collected blood conserves was not significantly different in these groups (5.4 in group C, 5.06 in group B, 4.8 in group A), but there was a significant difference in patients with a diminished hemoglobin (Hb < 14 g/dl): 5.2 in group C, 4.9 in group B, and 3.6 in group A. Patients with a normal hemoglobin level showed a significantly higher preoperative hemoglobin in group C against group A. We conclude that the application of EPO is suggestive in patients with a diminished hemoglobin, but also in patients with normal hemoglobin the blood picture at the time of surgery is higher in EPO treated patients.

Aged↗